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Objective: To investigate the use of tanezumab, a humanized monoclonal antibody that inhibits nerve
growth factor, for the treatment of moderate to severe osteoarthritis in Japanese patients.
Design: Patients received tanezumab 10, 25, 50, 100, 200 mg/kg, or placebo and were followed for 92 or
120 days. Endpoints included the incidence of adverse events (AEs) and the change from baseline to
week 8 in pain intensity and the Western Ontario and McMaster Universities Osteoarthritis (WOMAC)
subscales.
Results: Patients (n ¼ 83) were 69% female, age 44e73 years, with a KellgreneLawrence X-ray grade of
2e4. At week 8, compared with placebo, tanezumab 25, 100, and 200 mg/kg improved index knee pain
during walking (18.5, 14.3, and 27.6, respectively), index knee pain in the past 24 h (19.1, 14.6,
and 24.2, respectively), current index knee pain (16.5, 10.9, and 22.8, respectively), and the
WOMAC pain (11.5, 9.6, and 18.8, respectively), physical function (8.7, 9.5, and 17.6, respec-
tively), and stiffness (20.4, 11.2, and 10.2, respectively) subscales. Overall, seven patients reported
AEs of abnormal peripheral sensation: allodynia (two in the tanezumab 200 mg/kg group); paresthesia
(two in the tanezumab 200 mg/kg group), dysesthesia (one in the tanezumab 200 mg/kg group); ther-
mohypoesthesia (one in the tanezumab 100 mg/kg group), and decreased vibratory sense (one in the
placebo group). All of these AEs were mild to moderate in severity and transient in nature.
Conclusions: Tanezumab was safe and generally well tolerated and may improve pain symptoms in
Japanese patients with moderate to severe osteoarthritis of the knee.
ClinicalTrials.gov Identiﬁer: NCT00669409.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) of the knee, a condition characterized by
chronic pain and disability, has a signiﬁcant negative impact on the
quality of life of patients1. In Japan, approximately 25 million
patients have OA of the knee2 and this number is expected to
increase over the coming years as the Japanese elderly population
increases.
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are the current
mainstay therapy for the treatment of OA-related pain in Japan.S. Araki, Pﬁzer Global R&D,
-7, Yoyogi, Shibuya-ku, Tokyo
9-9060.
i).
nd of the paper.
s Research Society International. PWhile there are numerous reports of the superiority of NSAIDs over
placebo for the treatment of OA pain3,4, the analgesic activity of
NSAIDs can be variable among patients5,6. Furthermore, treatment
with NSAIDs is often accompanied by adverse drug reactions,
including upper gastrointestinal disorders, renal impairment, and
circulatory system disorders7e9. Non-drug therapies for OA such as
artiﬁcial knee replacement surgery, are becoming more frequent.
However, deformation of joint and cartilage to the point where
surgical intervention is required is generally accompanied by
severe pain. In summary, there is a current clinical need for novel
pharmacologic approaches that can treat moderate to severe OA
pain that is unresponsive to current analgesics.
Nerve growth factor (NGF) is a neurotrophin, which in devel-
opment plays a key role in the survival of sensory and sympathetic
neurons, but in the adult has a crucial role in the generation of pain
and hyperalgesia in chronic pain states through the sensitization ofublished by Elsevier Ltd. All rights reserved.
H. Nagashima et al. / Osteoarthritis and Cartilage 19 (2011) 1405e14121406nociceptive neurons10e13. Levels of NGF increase as a result of injury
or inﬂammation, and in chronic pain states including OA14e16.
Tanezumab is a humanized monoclonal antibody that selec-
tively binds and prevents NGF from activating TrkA receptors on
nociceptive neurons17. In a randomized, double-blind, placebo-
controlled, phase 2 trial, tanezumab demonstrated positive proof-
of-concept for the treatment of moderate to severe OA of the
knee in US patients18. We conducted a phase 1/2a trial to assess the
preliminary efﬁcacy, safety, and pharmacokinetic (PK) proﬁle of
tanezumab in Japanese patients with moderate to severe pain due
to OA of the knee.Methods
Study design
This randomized, double-blind, placebo-controlled, dose-
escalation, single intravenous (IV) dose, two-part study was con-
ducted in 12 study centers across Japan between June 2008 and
December 2009 (NCT00669409). All eligible patients entered
a screening period which lasted up to 35 days. During this period,
patients underwent a wash-out of existing pain medications (5
half lives of the medication) and were further assessed for eligi-
bility criteria. The study had two parts; part 1 was designed to
investigate the safety and tolerability and part 2 the preliminary
efﬁcacy of tanezumab in Japanese patients with OA (Fig. 1). Patients
were randomized to either Part 1 or Part 2 of the study and received
only a single dose of tanezumab.
Patients enrolled in part 1 of the study (n ¼ 42) were random-
ized to 1 of 5 cohorts and received a single IV dose of: tanezumab
10 mg/kg or placebo (injection solution containing 10 mM histidine,
275 mM sucrose, 0.01% Tween-20 pH 6.0) (Cohort A); tanezumab
25 mg/kg or placebo (Cohort B); tanezumab 50 mg/kg or placebo
(Cohort C); tanezumab 100 mg/kg or placebo (Cohort D); tanezumab
200 mg/kg or placebo (Cohort E). Cohorts AeE were consecutively
dosed, but only after the Risk Management Committee hadFig. 1. Studyconducted a blinded review of safety data collected from day 1 to
day 22 for the previous cohort. Cohorts A, B, and C were observed
for 92 days and Cohorts D and E were observed for 120 days.
Patients enrolled in part 2 of the study (n ¼ 41) were random-
ized to one of four cohorts and received a single IV dose of: tane-
zumab 10 mg/kg or placebo (Cohort F); tanezumab 25 mg/kg or
placebo (Cohort G); tanezumab 50 mg/kg or placebo (Cohort H);
tanezumab 100 mg/kg or placebo (Cohort I). Treatment of patients
in Cohorts F, G, and H began at the end of the 92-day observation
period for Cohorts A, B, and C, respectively. Treatment of patients in
Cohort I began on day 92 of the observation period of Cohort D.
For randomization, patients were given identiﬁcation numbers
by the investigator and were allocated to receive tanezumab or
placebo in one of the cohorts by the clinical trial registration center.
The patients, investigator, sponsor, and clinical trial collaborators at
the site, excluding the pharmacist and contract research organi-
zation persons in charge of unblinded monitoring, were blinded to
study drug assignment throughout the study period.
The study was conducted in compliance with the ethical prin-
ciples derived from the Declaration of Helsinki and in compliance
with all International Conference on Harmonization Good Clinical
Practice Guidelines. Each subject provided written informed
consent prior to study participation. The ﬁnal study protocol, any
amendments, and informed consent documentation, were
reviewed and approved by the Institutional Review Boards at each
of the participating investigational centers.Study population
Japanese male and female patients, aged 35e75 years, with
a diagnosis of OA of the knee based on the American College of
Rheumatology criteria19 with radiographic conﬁrmation (Kell-
greneLawrence20 X-ray grade of 2), unwilling or unable to take
non-opiate pain medications, or seeking invasive interventions
(e.g., intra-articular injections, knee arthroplasty), who had
completed ﬁve or more of the seven daily diary entries for baselinedesign.
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index knee pain during walking in the past 24 h of 50 to 90 mm
on a visual analog scale (VAS) at baseline (patients using arthritis
and painmedications prior to screening had an increase of10mm
in VAS score from screening to baseline).
Patients were excluded if they had a diagnosis, history, signs, or
symptoms of rheumatoid arthritis or ﬁbromyalgia, autoimmune
disorders, cancer (within the last 5 years, excluding cutaneous basal
cell or squamous cell cancer that was resolved by excision), clini-
cally signiﬁcant neurologic disease or a psychiatric disorder, clini-
cally signiﬁcant cardiac disease, allergic or anaphylactic reaction to
a therapeutic or diagnostic monoclonal antibody or immunoglob-
ulin (Ig) G-fusion protein, alcohol or drug dependence within the
last 5 years. They were also excluded if they had received intra-
articular corticosteroids, hyaluronic acid in the index knee within
the last 28 days, or arthroscopy or surgery on the index knee within
the last 6 months.
Rescue medications of acetaminophen 300mg to a maximum of
1500mg per day, or ibuprofen 200mg to amaximum of 600mg per
day, were allowed during the study. Rescue medications were not
permitted during the 24 h leading up to a clinic visit (excluding day
3 and day 4/5 clinic visits in part 1).Study assessments
The primary efﬁcacy endpointswere the change frombaseline to
week 8 in three measures of index knee pain intensity (pain during
walking in the past 24 h, pain in the past 24 h, and current pain) and
in the Western Ontario and McMaster Universities Osteoarthritis
(WOMAC)3.1 subscales (Japanese for Japan-V8). Patients recorded
these three measures of index knee pain in an electronic-diary (e-
diary) once daily before bedtime using a VAS ranging from 0 (no
pain) to 100 (extreme pain) mm. A 0e100mmVAS was also used to
assess WOMAC pain (ﬁve questions), physical function (17 ques-
tions), and stiffness (two questions) subscales. Patients also used the
e-diary to complete the WOMAC questionnaire at pre-speciﬁed
clinic visits (days 8, 15, 29, 57, 92, and 120, where applicable). For
the measures of index knee pain and the WOMAC subscales,
a reduction in VAS score indicated improvement.
PK of tanezumab was assessed using 3 ml blood samples
collected at pre-speciﬁed clinic visits. The samples were analyzed
for tanezumab concentrations at Prevalere Life Sciences, NY, USA.
Tanezumab samples were assayed using a validated, sensitive, and
speciﬁc enzyme-linked immunosorbent assay (ELISA).Fig. 2. Patient dAdverse events (AEs) were documented at each clinic visit.
Laboratory tests, vital signs and postural vital signs, the Hopkins
Verbal Learning Test-Revised (HVLT-R)21, and an electrocardio-
gram (ECG), were carried out during pre-speciﬁed clinic visits, as
were neurologic examinations including mental status, cranial
nerves, motor, sensory, cerebellar/coordination, reﬂexes, and gait. If
an AE suggestive of new or worsening peripheral neuropathy or
dysesthesia, paresthesia, allodynia, hypoesthesia, or hyperesthesia
was reported, or if the investigator detected clinically signiﬁcant
abnormalities, the patient was to be referred to a neurologist. Blood
samples (3 ml) for anti-tanezumab antibody [anti-drug antibody
(ADA)] analysis were collected at pre-dose for all cohorts and again
at day 92 for cohorts A, B, C, F, G, and H and at day 120 for cohorts D,
E, and I. Serum samples were analyzed at Prevalere Life Sciences for
the presence of anti-tanezumab antibodies following a tiered
approach using screening, conﬁrmation, and titer/quantitation.
Statistical methods
The planned sample size was 80 patients, divided into the
following groups: 14 patients for placebo; 15 patients each for
tanezumab 10, 25, 50, and 100 mg/kg; and six patients for tanezu-
mab 200 mg/kg. The sample size was based on the results of
a previous study in patients with knee OA (ClinicalTrials.gov
identiﬁer, NCT00394563)18. Assuming that the difference in the
least square (LS) mean change from baseline toweek 8 in VAS score
for index knee pain during walking in the past 24 h for tanezumab
100 mg/kg vs placebo was 28.0, and the standard deviation (SD)
was 25.4, 14 patients per group would be necessary to demonstrate
the superiority of tanezumab vs placebo with a signiﬁcance level of
0.05 and a power of 80% by the two-sided t-test. For the tanezumab
200 mg/kg group, the number of patients was limited to the patients
enrolled in part 1, and efﬁcacy was evaluated for reference only.
For efﬁcacy analyses, the primary population was the full anal-
ysis set (FAS), which included all patients who had received study
medication and completed 1 entry pre- and post-treatment. Pain
intensity data and WOMAC pain, physical function, and stiffness
subscales were analyzed using the mixed model of repeated
measures (MMRM) with the change from baseline in VAS scores as
the repeated response variable. The model included ﬁxed effects of
treatment, week, treatment by week, study part, and baseline
values. The covariance structure used to model within patients
errors was deﬁned as autoregressive process of order 1. WOMAC
pain, physical function, and stiffness subscales at week 8 were also
analyzed using the analysis of covariance (ANCOVA) model, withisposition.
Table I
Baseline patient characteristics, by treatment group
Tanezumab dose (mg/kg) Placebo
10 25 50 100 200
n ¼ 15 n ¼ 15 n ¼ 15 n ¼ 16 n ¼ 6 n ¼ 16
Gender, n (%)
Male 5 (33.3) 7 (46.7) 4 (26.7) 4 (25.0) 1 (16.7) 5 (31.3)
Female 10 (66.7) 8 (53.3) 11 (73.3) 12 (75.0) 5 (83.3) 11 (68.8)
Age, years
Mean (SD) 59.3 (3.6) 57.3 (4.7) 60.7 (6.3) 58.1 (7.0) 60.0 (4.2) 59.4 (5.6)
Range 54e65 48e62 49e72 44e73 53e64 48e72
Weight, kg
Mean (SD) 69.8 (11.6) 72.6 (15.4) 62.7 (7.8) 63.4 (13.4) 55.1 (10.9) 67.4 (13.2)
Range 52.3e89.4 43.7e107.2 48.8e75.7 45.1e90.3 41.8e73.3 44.9e101.7
KellgreneLawrence X-ray grade, n (%)
Grade 2 7 (46.7) 9 (60.0) 14 (93.3) 11 (68.8) 3 (50.0) 8 (50.0)
Grade 3 8 (53.3) 6 (40.0) 1 (6.7) 5 (31.3) 3 (50.0) 7 (43.8)
Grade 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3)
Duration of knee OA, years
Mean (SD) 4.5 (3.8) 7.3 (5.4) 4.2 (5.0) 3.8 (3.1) 5.4 (7.4) 7.9 (10.1)
Range 1.0e15.3 0.8e19.4 0.8e20.6 0.9e10.6 0.9e20.5 0.6e37.0
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The method of baseline observation carried forward (BOCF) was
used to impute for missing data.
Results
Patient disposition
Overall, 83 patients were randomized and received treatment
and of these 82 (98.8%) completed the study (Fig. 2). There were
more females than males in all treatment groups (Table I). Patients
were aged 44e73 years and most had a KellgreneLawrence X-ray
grade of 2 or 3. Overall, 11 patients (tanezumab 10 mg/kg: 6; 25 mg/
kg: 0; 50 mg/kg: 1; 100 mg/kg: 2; 200 mg/kg: 1; placebo: 1) received
hyaluronic acid and none received intra-articular steroids in the
index knee prior to 28 days of the start of study treatment.
Efﬁcacy
At week 8, tanezumab 25, 100, and 200 mg/kg, but not 10 and
50 mg/kg, improved all three measures of index knee pain
compared with placebo (difference from placebo of 10 points;
Table II). Tanezumab 25,100, and 200 mg/kg also improvedWOMACTable II
MMRM analysis of changes from baseline to week 8 in index knee pain during walking
Endpoint
10 25
n ¼ 15 n ¼ 15
Index knee pain
during walking
in the past 24 h
Baseline (SD) 74.9 (10.1) 69.4 (10.5
LS mean change from
baseline to week 8 (SE)
16.3 (5.7) 41.6 (5.
LS mean difference
from placebo (95% CI)
6.8
(9.6, 23.2)
18.5
(34.8, 
Index knee pain
in the past 24 h
Baseline (SD) 75.4 (9.3) 67.3 (11.2
LS mean change from
baseline to week 8 (SE)
19.0 (5.7) 41.8 (5.
LS mean difference
from placebo (95% CI)
3.7
(12.5, 19.9)
19.1
(35.2, 
Current index
knee pain
Baseline (SD) 66.5 (22.6) 64.5 (12.5
LS mean change from
baseline to week 8 (SE)
17.5 (5.4) 40.2 (5.
LS mean difference from
placebo (95% CI)
6.3
(9.2, 21.7)
16.5
(31.9, 
CI: conﬁdence interval.
* Two patients in the placebo group were excluded from the FAS because they had inpain (ANCOVA analysis of LS mean difference from placebo [95% CI]
for 25 mg/kg:8.6 [23.3, 6.2]; 100 mg/kg:7.0 [21.5, 7.5]; 200 mg/
kg: 19.7 [38.9, 0.5]), physical function (25 mg/kg: 6.9 [21.9,
8.2]; 100 mg/kg: 7.6 [22.6, 7.4]; 200 mg/kg: 19.3 [38.9, 0.3]),
and stiffness (25 mg/kg: 18.4 [33.4, 3.5]; 100 mg/kg: 9.2
[23.9, 5.6]; 200 mg/kg: 12.0 [31.4, 7.4]) subscales at week 8
compared with placebo. Similar improvements in the tanezumab
25, 100, and 200 mg/kg groups were also shown in the MMRM
analysis of the WOMAC subscales at week 8 [difference from
placebo of 8 points; Fig. 3(AeC) respectively]. Figure 3(AeC)
indicates that across all of the tanezumab dose groups, the change
from baseline in WOMAC pain, physical function, and stiffness
subscales decreased fromweek 1 to week 2 before increasing again
at week 4; this trend was not observed in the placebo group as the
change from baseline for all of the WOMAC subscales increased
from week 1 to week 2 and then increased again or remained the
same at week 4.Pharmacokinetics
Following single IV infusion of 10e200 mg/kg of tanezumab to
OA patients, systemic exposure of tanezumab [area under the curve
from time 0 to inﬁnity (AUCinf) and maximum plasmain the past 24 h, index knee pain in the past 24 h, and current index knee pain, FAS
Tanezumab dose (mg/kg) Placebo
50 100 200
n ¼ 15 n ¼ 16 n ¼ 6 n ¼ 14*
) 72.3 (6.6) 69.3 (10.5) 75.5 (7.6) 69.9 (14.6)
7) 27.1 (5.7) 37.4 (5.5) 50.7 (9.3) 23.1 (5.9)
2.2)
4.0
(20.3, 12.3)
14.3
(30.4, 1.8)
27.6
(49.0, 6.2)
e
) 70.6 (8.6) 67.8 (10.7) 69.0 (11.4) 68.0 (14.3)
6) 28.4 (5.6) 37.3 (5.4) 46.9 (9.0) 22.7 (5.8)
3.1)
5.7
(21.7, 10.3)
14.6
(30.4, 1.3)
24.2
(45.1, 3.3)
e
) 67.9 (8.4) 65.0 (13.8) 69.7 (9.3) 62.3 (18.9)
4) 26.8 (5.4) 34.6 (5.2) 46.6 (8.8) 23.7 (5.6)
1.0)
3.1
(18.5, 12.4)
10.9
(26.1, 4.4)
22.8
(43.1, 2.5)
e
jection site swelling and stopped the IV infusion prior to completion.
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(Table III). Across the tanezumab dose range, the median time to
Cmax (Tmax) ranged from 0.33 h to 1 h and the mean half life (T1/2) of
tanezumab ranged from 12.5 to 23.5 days.
Safety
There were no study discontinuations due to AEs (Table IV).
Across all the tanezumab groups, the percentage of patients
experiencing 1 AE was lowest in the 25 mg/kg group (4/15
patients, 26.7%) and highest in the 200 mg/kg group (6/6 patients,
100%). The frequency of AEs was smaller in the combined tanezu-
mab groups (36/67 patients, 53.7%) than in the placebo groupFig. 3. MMRM analysis of LS mean change from baseline in WOMAC pain (A), phys(13/16 patients, 81.3%). Most of the AEs were mild or moderate in
severity. Three serious AEs (SAEs) were reported: inguinal hernia
(tanezumab 10 mg/kg group); atrioventricular block (tanezumab
25 mg/kg group) and contusion (prior to study drug administration).
None of the SAEs were considered to be related to the study drug
and were resolved or resolving at the end of the study. Nasophar-
yngitis was the most frequently reported AE in both the tanezumab
(6/67 patients, 9.0%) and placebo (5/16 patients, 31.3%) groups.
A total of ﬁve different AEs of abnormal peripheral sensation
were reported: allodynia (two patients in the tanezumab 200 mg/kg
group), paresthesia (two patients in the tanezumab 200 mg/kg
group), dysesthesia (one patient in the tanezumab 200 mg/kg
group), thermohypoesthesia (one patient in the tanezumab 100 mg/ical function (B), and stiffness (C) subscales, over time, FAS. SE: standard error.
Table III
Summary of plasma tanezumab PK parameter values
Parameter Tanezumab dose (mg/kg)
10 25 50 100 200
n ¼ 6*, 6y n ¼ 5*,z, 4y n ¼ 5*,z, 5y n ¼ 6*, 5y n ¼ 6*, 6y
AUCinf (mg* h/ml) 72.1 (45) 158 (16) 312 (12) 852 (31) 1890 (20)
Cmax (mg/ml) 0.309 (17) 0.682 (32) 1.05 (13) 2.40 (14) 4.79 (14)
Tmax (h) 0.334 (0.167e1.00) 0.500 (0.167e24.0) 1.00 (0.183e4.03) 0.750 (0.167e1.00) 0.750 (0.217e12.0)
T1/2 (day) 12.5 (6.43) 12.8 (4.25) 13.0 (2.02) 15.6 (4.57) 23.5 (5.41)
CL (ml/day/kg) 3.33 (60) 3.81 (16) 3.84 (13) 2.82 (44) 2.55 (16)
Vz (ml/kg) 51.1 (31) 67.5 (43) 71.1 (15) 60.2 (15) 84.3 (15)
MRT (day) 17.5 (8.95) 18.1 (4.63) 19.9 (3.67) 23.2 (6.36) 33.0 (6.79)
AUCinf: area under the curve from 0 h to inﬁnity; Cmax: maximumplasma concentration; Tmax: time tomaximumplasma concentration; T1/2: half life; CL: clearance; Vz: volume
of distribution; MRT:mean residence time. AUCinf, Cmax, CL, and Vz are presented as geometric mean (coefﬁcient of variation %); T1/2 andMRT are presented as arithmetic mean
(SD); Tmax is presented as median (range).
* Number of patients included in the summary statistics.
y Number of patients contributing to the mean for AUCinf, T1/2, CL, Vz, and MRT.
z Two patients were excluded from the summary statistics due to anomalous proﬁles.
Table IV
Incidence of AEs by treatment group
Tanezumab dose (mg/kg) Placebo
10 25 50 100 200
n ¼ 15 n ¼ 15 n ¼ 15 n ¼ 16 n ¼ 6 n ¼ 16
Study discontinuations, n (%)
All 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3)* 0 (0.0) 0 (0.0)
AEs, n (%)
All-cause 9 (60.0) 4 (26.7) 9 (60.0) 8 (50.0) 6 (100.0) 13 (81.3)
Treatment-related 3 (20.0) 0 (0.0) 1 (6.7) 4 (25.0) 6 (100.0) 7 (43.8)
SAEs, n (%)
All-cause 1 (6.7) 1 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Treatment-related 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Most common AEsy, n (%)
Nasopharyngitis 2 (13.3) 0 (0.0) 2 (13.3) 2 (12.5) 0 (0.0) 5 (31.3)
Headache 1 (6.7) 0 (0.0) 0 (0.0) 2 (12.5) 1 (16.7) 1 (6.3)
Most common AEs of abnormal peripheral sensationz, n (%)
Allodynia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0)
Paresthesia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0)
* The patient was no longer willing to participate in the study because it became
impossible to visit hospital.
y >3 patients across the tanezumab groups.
z 2 patients across the tanezumab groups.
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placebo group). The AEs of abnormal peripheral sensation were all
considered to be treatment-related; however, all were mild or
moderate in severity and resolved without requiring treatment.
A neurologic consultation was performed for ﬁve of six patients
who had AEs of abnormal peripheral sensation. For all ﬁve patients,
no clinically signiﬁcant abnormalities were reported by the
neurologist. For the sixth patient, the investigator judged that the
AE was so mild that it did not meet the criteria for an additional
neurologic consultation.
Three tanezumab-treated patients reported treatment-related
ECG AEs: supraventricular extrasystoles (10 mg/kg group); supra-
ventricular extrasystoles and ECG T-wave abnormal (100 mg/kg
group); and decreased ECG T-wave amplitude (200 mg/kg group).
All treatment-related ECG AEs were mild in severity and had
resolved by the end of the study. Three tanezumab-treated patients
reported treatment-related laboratory test AEs (increased blood
creatine phosphokinase, 10 and 100 mg/kg groups; neutropenia,
200 mg/kg group), all of which were mild in severity.
There were no notable differences between the tanezumab
groups and placebo for vital signs, postural signs, and the HVLT-R.
ADA production was not detected in any of the patients.
Discussion
At 8 weeks post-treatment with a single IV dose, tanezumab 25,
100, and 200 mg/kg demonstrated preliminary efﬁcacy vs placebo in
reducing VAS scores for pain intensity (index knee pain during
walking in the past 24 h, index knee pain in the past 24 h, and
current index knee pain) and the WOMAC subscales (pain, physical
function, and stiffness). However, at doses of 10 and 50 mg/kg, the
effect of tanezumab on these efﬁcacy endpoints was not substan-
tially different from placebo. A previous study in patients with knee
OA from the US18 showed tanezumab to be effective in reducing
pain at doses of 10 and 50 mg/kg, and so the reason for the lack of
efﬁcacy of tanezumab at these doses in the present study is unclear.
Compared with the other treatment groups, patients randomized
to the 50 mg/kg tanezumab dose group had higher pain intensity
and WOMAC VAS scores at baseline, and therefore this might
explain the disparity in efﬁcacy between this and the 25, 100, and
200 mg/kg doses. Interestingly, independent of dose, the efﬁcacy of
tanezumab for all of the WOMAC subscales (change from baseline)
seemed to decrease at week 2 before increasing again at week 4.
The reason for the relative loss of efﬁcacy at week 2 is not well
understood. It is possible that there may be a relationship between
this effect and the coincident onset of AEs such as allodynia,dysesthesias and paresthesias which may be uncomfortable in
some patients. An alternative hypothesis is that there may be some
residual NGF activity capable of pain signaling in the bound NGF-
antibody complex, the concentration of which rises and peaks at
the same time as the relative loss of efﬁcacy and then wanes as the
complex is metabolized. Further multiple-dose studies of tanezu-
mab in Japanese patients with OA are needed to investigate these
observations.
Linear PK was shown by increased systemic exposurewith dose.
The reason for the anomalies in the PK is not well understood and
requires further investigation. The PK appeared to agree with the
dose but the dose response with regard to efﬁcacy was not clear
due to large variability and the small sample size.
In this study, tanezumab was safe and generally well tolerated.
There were fewer AEs in the combined tanezumab groups than in
the placebo group and most of these AEs were mild or moderate in
severity. Previous studies have suggested that it is unlikely that an
anti-NGF antibody would cross the bloodebrain barrier and cause
any AEs related to the central nervous system22. In the present
study, there were no notable differences in memory function by
HVLT-R between patients in the tanezumab groups and placebo,
further suggesting that the effects of tanezumab are limited to the
peripheral nervous system. As in the phase 2 trial of tanezumab in
H. Nagashima et al. / Osteoarthritis and Cartilage 19 (2011) 1405e1412 1411US patients with OA18, tanezumab-treated patients in the present
study experienced a higher percentage of abnormal peripheral
sensation AEs compared with placebo-treated patients. All of these
AEs were mild or moderate in severity and resolved without
requiring treatment. Also, for those patients with AEs of abnormal
peripheral sensationwhowere sent for a neurological consultation,
no clinically signiﬁcant abnormalities were reported by the
neurologist.
The limitations of this study include: the small sample size,
which prevented a more thorough analysis of the efﬁcacy of tane-
zumab by dose; the limited (single dose) and short-term (13 or 17
weeks) exposure of patients to tanezumab (given that OA knee pain
usually requires long-term treatment); and the absence of an active
treatment armwith which the tanezumab data could be compared.
However, this was the ﬁrst clinical trial of tanezumab in Japanese
patients and was primarily performed to investigate the safety and
preliminary efﬁcacy of tanezumab in this population. Analysis of
tanezumab in a longer, multiple-dose, dose-ranging study with
a larger sample size is required to further investigate the safety and
tolerability and optimal dose of tanezumab in Japanese patients
with OA.
Through May 24, 2010, 16 subjects participating in one of 13
phase 3 studies of OA of the hip or knee developed progressively
worsening OA associated with radiographic evidence of bone
necrosis that required total joint replacements. The affected joints
included the knee, hip, or shoulder (predominately unilateral
involvement), with over one-half of the cases occurring in a joint
other than the index joint under evaluation in the study. These 16
events led the US Food and Drug Administration (FDA) on June 22,
2010 to put the OA clinical program for tanezumab on clinical hold
until more information can be obtained to determine the true
incidence and the causality of these events.
In summary, in this randomized, placebo-controlled, double-
blind, phase 2 study in Japanese patients with moderate to severe
OA of the knee, tanezumab (25, 100, and 200 mg/kg) demonstrated
preliminary efﬁcacy vs placebo and was safe and generally well
tolerated. Further studies investigating the use of tanezumab for
the treatment of knee OA pain in Japanese patients are warranted.
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